October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…
New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health…
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
October 03, 2025 16:05 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…
October 03, 2025 16:15 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…
October 02, 2025 10:00 ET | Source: Cirrus Therapeutics, Inc. Cirrus’ lead program is a novel AAV gene therapy designed…
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF”…